Fuhrman Barbara J, Feigelson Heather Spencer, Flores Roberto, Gail Mitchell H, Xu Xia, Ravel Jacques, Goedert James J
Department of Epidemiology (B.J.F.), Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205; Divisions of Cancer Epidemiology and Genetics (B.J.F., R.F., N.H.G., J.J.G.) and Cancer Prevention (R.F.), National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-9704; Institute for Health Research (H.S.F.), Kaiser Permanente Colorado, Denver, Colorado 80231; Cancer Research Technology Program (X.X.), Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702; and Institute for Genome Sciences (J.R.), University of Maryland, Baltimore, Maryland 21201.
J Clin Endocrinol Metab. 2014 Dec;99(12):4632-40. doi: 10.1210/jc.2014-2222.
The gut microbiota may influence the risk of breast cancer through effects on endogenous estrogens.
The objective of the study was to investigate whether urinary estrogens and estrogen metabolites are associated with the diversity and composition of the fecal microbiome.
This was a cross-sectional study among women enrolled in Kaiser Permanente of Colorado.
A total of 60 women drawn from a random sample of healthy postmenopausal women (aged 55-69 y), without current or recent use of antibiotics or hormone therapy and no history of cancer or gastrointestinal disease participated in the study. OUTCOME MEASURES AND METHODS: Creatinine-standardized urinary estrogens (estrone and estradiol) and 13 hydroxylated estrogen metabolites were measured in spot urines by liquid chromatography-tandem mass spectrometry. The fecal microbiome was assessed using pyrosequencing of 16S rRNA amplicons. General linear models were used to test for associations of diversity and composition of the fecal microbiome with parent estrogen (estrone + estradiol), total estrogens, and estrogen metabolites and the ratio of estrogen metabolites to parent estrogen, which has been predictive of postmenopausal breast cancer risk in previous studies.
The ratio of metabolites to parents was directly associated with whole-tree phylogenetic diversity (R = 0.35, P = .01). Relative abundances of the order Clostridiales (R = 0.32, P = .02) and the genus Bacteroides (R = -0.30, P = .03) were also correlated with the ratio of metabolites to parents. Associations were independent of age, body mass index, and study design factors.
Our data suggest that women with a more diverse gut microbiome exhibit an elevated urinary ratio of hydroxylated estrogen metabolites to parent estrogen. Further research is warranted to confirm and relate these findings to clinical disease.
肠道微生物群可能通过对内源性雌激素的影响来影响乳腺癌风险。
本研究的目的是调查尿雌激素和雌激素代谢产物是否与粪便微生物群的多样性和组成有关。
这是一项对科罗拉多州凯撒医疗集团登记的女性进行的横断面研究。
从健康绝经后女性(年龄55 - 69岁)的随机样本中抽取了60名女性,她们目前未使用抗生素或激素治疗,且无癌症或胃肠道疾病史,参与了本研究。
通过液相色谱 - 串联质谱法测量即时尿样中肌酐标准化的尿雌激素(雌酮和雌二醇)以及13种羟基化雌激素代谢产物。使用16S rRNA扩增子焦磷酸测序评估粪便微生物群。使用一般线性模型来测试粪便微生物群的多样性和组成与母体雌激素(雌酮 + 雌二醇)、总雌激素、雌激素代谢产物以及雌激素代谢产物与母体雌激素的比值之间的关联,在先前的研究中,该比值可预测绝经后乳腺癌风险。
代谢产物与母体的比值与全树系统发育多样性直接相关(R = 0.35,P = 0.01)。梭菌目(R = 0.32,P = 0.02)和拟杆菌属(R = -0.30,P = 0.03)的相对丰度也与代谢产物与母体的比值相关。这些关联独立于年龄、体重指数和研究设计因素。
我们的数据表明,肠道微生物群更多样化的女性尿中羟基化雌激素代谢产物与母体雌激素的比值升高。有必要进行进一步研究以证实这些发现并将其与临床疾病联系起来。